# US 2016/0258931 A1 · Method for selecting cancer treatment regimen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0258931 A1
- Document ID: US20160258931A1
- Status: Published application
- Kind: A1
- Application number: 15/036,951
- Filed: 2014-11-14
- Published: 2016-09-08
- Earliest claimed: 2013-11-15
- Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Inventors: Ariosto S. Silva; Zayar P. Khin
- Web page: https://patentgrep.com/patent/US20160258931A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- C12M 41/46: {of cellular or enzymatic activity or functionality, e.g. cell viability}
- G01N 15/1433: using image recognition
- G01N 15/1484: {microstructural devices}
- G01N 33/5047: {Cells of the immune system}
- G01N 33/57505: of the blood, e.g. leukaemia
- A61B 2010/0258: {Marrow samples}
- G01N 21/6458: {Fluorescence microscopy (fluorescence microscopes per se G02B21/0076 and G02B21/16)}
- G01N 21/763: {Bioluminescence}
- G01N 2015/1006: {for cytology}
- G01N 2201/0221: Portable; cableless; compact; hand-held
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Disclosed is a method for selecting a cancer treatment regimen for a subject.

## Claims

### Claim 1

A method comprising
(a) culturing a plurality of cells from a subject in a chamber;
(b) contacting the cells in the chamber with an active agent;
(c) capturing a first optical signal from the cells contacted with the active agent at a first time point;
(d) capturing a second optical signal from the cells contacted with the active agent at a second time point;
(e) analyzing the first optical signal and the second optical signal to detect cell membrane motion of the cells; and
(f) analyzing the cell membrane motion to quantify the viability of the cells following contact with the active agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first optical signal, the second optical signal, or a combination thereof comprises an image.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first optical signal, the second optical signal, or a combination thereof comprises a bright field image.

### Claim 4 (depends on 1)

The method of claim 1, wherein the absence of cell membrane motion indicates cell death.

### Claim 5 (depends on 1)

The method of claim 1, further comprising collecting parameters to generate a multi-parameter model that summarizes the response of the subject to the active agent.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cells comprise cancer cells.

### Claim 7 (depends on 6)

The method claim 6, further comprising selecting a cancer treatment regimen for the subject based on the results of the multi-parameter model.

### Claim 8 (depends on 6)

The method of claim 6, wherein the cancer comprises a hematological cancer.

### Claim 9 (depends on 6)

The method of claim 6, wherein the cancer comprises multiple myeloma.

### Claim 10 (depends on 6)

The method of claim 6, wherein chamber recapitulates the cancer microenvironment.

### Claim 11 (depends on 10)

The method of claim 10, wherein the chamber comprises extracellular matrix, subject-derived stroma, and growth factors to recapitulate the cancer microenvironment.

### Claim 12 (depends on 1)

The method of claim 1, wherein the chamber comprises a microfluidic chamber.

### Claim 13 (depends on 1)

The method of claim 1, wherein the chamber comprises a well in a multiwell-plate.

### Claim 14

A method comprising:
(a) preparing a dose-response curve by assessing the viability of a plurality of cells from a subject in response to a an active agent at a plurality of time points;
(b) utilizing the dose-response curve to develop a multi-parameter model, wherein the multi-parameter model describes the rate of accumulation of damage in the cells due to the active agent and the active agent-induced cell death due to the accumulated damage;
(c) utilizing the multi-parameter model and the dose-response curve to determine the number of populations in the sample; and
(d) utilizing the number of populations and the multi-parameter model to predict a response of the subject to the active agent.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The method of claim 1, further comprising collecting a sample from the subject and isolating the cells from the sample.

### Claim 21 (depends on 20)

The method of claim 20, wherein the sample comprises a bone marrow aspirate.

### Claim 22 (depends on 1)

The method of claim 1, wherein the active agent comprises an anticancer agent.

### Claim 23 (depends on 1)

The method of claim 1, wherein the method predicts an initial response of the subject to the active agent.

### Claim 24 (depends on 1)

The method of claim 1, wherein the method predicts the chance of progression-free survival.

### Claim 25 (depends on 1)

The method of claim 1, wherein the method predicts the chance of developing environment-mediated resistance to the active agent.

### Claim 26 (depends on 1)

The method of claim 1, wherein the active agent comprises a combination of active agents.

### Claim 27 (depends on 1)

The method of claim 1, wherein the method predicts an effective dosing schedule of the active agent.

### Claim 28 (depends on 1)

The method of claim 1, wherein method predicts an effective concentration of the active agent.

### Claim 29 (depends on 1)

The method of claim 1, wherein the active agent comprises, melphalan, bortezomib, FAM-HYD-1, Marizomib (NPI-0052), Carfilzomib, Cytoxan, Dexamethasone, Thalidomide, Lenalidomide, Oprozomib, Panobinostat, Quisinostat, Selinexor, or a combination thereof.

### Claim 30

A method for selecting a cancer treatment regimen for a subject, comprising:
(a) administering cancer cells from the subject to a microfluidic chamber that recapitulates the cancer microenvironment and comprises a linear drug gradient across the chamber;
(b) identifying cell death induced by the drug across the drug gradient at one or more time points;
(c) collecting parameters from the assay to generate a multi-parameter model that summarizes the response of the subject to the drug treatment; and
(d) selecting a cancer treatment regimen for the subject based on the results of the multi-parameter model.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)
